Phase I Study Of Flavopiridol And Docetaxel (Taxotere) In Patients With Advanced Cancers

Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically or cytologically confirmed metastatic or unresectable solid tumor

- No standard relatively effective curative or palliative measures exist

- Measurable disease in at least 1 dimension

- At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan

- No known clinically active and uncontrolled brain metastases

PATIENT CHARACTERISTICS:

Age:

- 18 and over

Performance status:

- ECOG 0-2

- Karnofsky 60-100%

Life expectancy:

- More than 12 weeks

Hematopoietic:

- WBC at least 3,000/mm^3

- Absolute neutrophil count at least 1,500/mm^3

- Platelet count at least 100,000/mm^3

Hepatic:

- Bilirubin normal

- ALT/AST no greater than 1.5 times upper limit of normal (ULN)

- Alkaline phosphatase no greater than 2.5 times ULN

Renal:

- Creatinine normal

Cardiovascular:

- No symptomatic congestive heart failure

- No unstable angina pectoris

- No cardiac arrhythmia

Other:

- No prior allergic reactions to compounds of similar chemical or biologic composition
to flavopiridol or docetaxel

- No other uncontrolled concurrent illness that would preclude study participation

- No ongoing or active infection

- No psychiatric illness or social situations that would preclude study compliance

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy:

- No concurrent immunotherapy

Chemotherapy:

- At least 6 months since prior taxane therapy

- At least 4 weeks since other prior chemotherapy (6 weeks for nitrosoureas or
mitomycin) and recovered

- No other concurrent chemotherapy

Endocrine therapy:

- No concurrent hormonal therapy except contraceptives, appetite stimulants, or
replacement steroids

Radiotherapy:

- At least 4 weeks since prior radiotherapy and recovered

- No concurrent radiotherapy

Surgery:

- See Disease Characteristics

Other:

- No other concurrent investigational agents

- No concurrent combination antiretroviral therapy for HIV-positive patients